Autosomal Dominant Polycystic Kidney
24
5
10
8
Key Insights
Highlights
Success Rate
73% trial completion
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
12.5%
3 terminated out of 24 trials
72.7%
-13.8% vs benchmark
29%
7 trials in Phase 3/4
75%
6 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (24)
Renal Oxygen Consumption, Insulin Sensitivity, and Daily Caloric Restriction in ADPKD
Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases
A Prospective Observational Study of Foam Sclerotherapy .
Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)
Outcome of ADPKD With Octreotide LAR
Treatment of Vascular Stiffness in ADPKD
Daily Caloric Restriction in ADPKD
Effect of Beetroot Juice on Reducing Hypertension in Autosomal Dominant Polycystic Kidney Disease
An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON
Statin Therapy in Patients With Early Stage ADPKD
Glucagon-Like Peptide-1 Receptor Agonist in ADPKD
Analysis of Patients With Autosomal Dominant Polycystic Kidney
Thyroid Hormones in ADPKD
Dietary Intervention in ADPKD on Tolvaptan
A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney Disease
Assessment of Treatment With Laparoscopic Fenestration or Aspiration Sclerotherapy for Large Symptomatic Hepatic Cysts
Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD